PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
59.34
ESG score 90-95% of Biotechnology median of 62.52. John Neff would demand higher returns to compensate for below-average ESG risk management.
58.68
Environmental score near Biotechnology median of 57.67. David Dodd would investigate if industry-standard environmental practices adequately address climate risks.
58.17
Social score 80-90% of Biotechnology median of 65.34. Martin Whitman would look for hidden social liabilities and reputational risks.
61.16
Governance score near Biotechnology median of 63.90. David Dodd would investigate if industry-standard governance adequately protects shareholder interests.